Sun Pharmaceutical Industries Ltd., India’s largest pharmaceutical company, has announced promising results from a clinical trial for MM-II, a new non-opioid therapy for knee osteoarthritis pain relief. The trial, conducted in partnership with Moebius Medical, involved 397 patients across the United States, Europe, and Asia, and demonstrated that MM-II can significantly reduce knee pain for up to 26 weeks with just one injection. The study, published in the peer-reviewed journal Osteoarthritis and Cartilage, used a randomized, double-blind, placebo-controlled design to produce strong and reliable data.
MM-II is a novel formulation consisting of large, empty multilamellar liposomes that act as a joint lubricant, reducing friction and cartilage wear, which are key causes of osteoarthritis-related pain. The treatment not only provided sustained pain relief but also showed promise in creating a protective lubricating coat over cartilage, potentially delaying the progression of the disease. According to Dr. Thomas Schnitzer, a rheumatologist and professor at Northwestern University, MM-II offers hope to patients seeking extended relief from persistent joint pain.
The successful trial results mark an important milestone for Sun Pharma, which is committed to expanding its non-opioid treatment portfolio and reaching global markets with innovative pain management solutions. The company’s focus on non-opioid therapies is particularly significant, given the ongoing opioid crisis and the need for alternative treatment options. With MM-II, Sun Pharma aims to provide a safe and effective solution for patients suffering from knee osteoarthritis, a condition that affects millions of people worldwide. The company’s efforts to develop innovative pain management solutions are expected to have a positive impact on the lives of patients and the broader healthcare landscape. Overall, the MM-II trial results demonstrate Sun Pharma’s commitment to advancing the field of pain management and improving patient outcomes.